Table 2.
Ceramides after Desipramine, Zoledronic Acid or Sphingolactone treatment
| Sphingolipid | Control (n=5) | Control + Sph (n=9) | Control + ZA (n=9) | Control + Des (n=10) | Elastase (n=5) | Elastase + Sph (n=9) | Elastase + ZA (n=9) | Elastase + Des (n=10) |
|---|---|---|---|---|---|---|---|---|
| Ceramide 16:0 |
23.39 ± 2.92 |
25.55 ± 1.23 |
26.07 ± 2.85 |
32.70 ± 3.12 * |
48.38 ± 4.46 * |
53.07 ± 12.34 *$ |
44.47 ± 11.93 *$ |
63.15 ± 13.15 *#$ |
| Ceramide 18:0 |
2.61 ± 0.54 |
2.74 ± 0.30 |
2.83 ± 0.20 |
4.01 ± 0.70 |
4.88 ± 0.60 * |
5.66 ± 1.62 *$ |
4.43 ± 0.97 *$ |
7.45 ± 1.32 *#$ |
| Ceramide 20:0 |
1.30 ± 0.34 |
1.24 ± 0.12 |
1.32 ± 0.14 |
1.97 ± 0.27 |
2.56 ± 0.37 * |
2.86 ± 0.78 *$ |
2.44 ± 0.37 *$ |
4.07 ± 0.82 *#$ |
| Ceramide 22:0 |
7.95 ± 2.41 |
7.37 ± 0.70 |
9.75 ± 1.29 |
14.17 ± 1.89 * |
20.01 ± 4.39 * |
20.43 ± 5.74 *$ |
19.80 ± 4.73 *$ |
33.90 ± 7.71 *#$ |
| Ceramide 24:0 |
33.63 ± 13.22 |
25.92 ± 2.66 |
42.31 ± 6.19 |
56.01 ± 6.39 * |
86.39 ± 22.72 * |
71.40 ± 16.60 *$ |
84.40 ± 16.74 *$ |
145.10 ± 41.79 *#$ |
| Ceramide 24:1 |
19.09 ± 6.27 |
17.97 ± 0.90 |
22.81 ± 4.10 |
33.25 ± 4.01 * |
68.45 ± 19.42 * |
64.66 ± 16.75 *$ |
70.20 ± 16.85 *$ |
113.70 ± 26.87 *#$ |
| Dihydro Ceramide 18:0 |
0.32 ± 0.07 |
0.38 ± 0.23 |
0.39 ± 0.30 |
0.42 ± 0.08 |
0.88 ± 0.21 * |
1.02 ± 0.35 *$ |
0.86 ± 0.20 *$ |
1.76 ± 0.24 *#$ |
| Dihydro Ceramide 24:0 | 1.57 ± 0.67 | 1.67 ± 0.75 | 2.02 ± 1.11 | 2.32 ± 1.78 | 6.54 ± 1.78 * | 6.28 ± 2.49 *$ | 6.29 ± 1.52 *$ | 13.11 ± 5.03 *#$ |
BAL fluid was collected and processed using LCMS. Data are expressed as Mean + SEM in ng/ml BAL fluid. Des = Desimaprimine, ZA = Zoledronic Acid, Sph = Sphingolactone. *p<0.05 when compared to Control. # p<0.05 when compared to Elastase. $p<0.05 when compared to control group with the same inhibitor (Elastase + Sph vs. Control + Sph, Elastase + ZA vs. Control + ZA, Elastase + Des vs. Control + Des).